jRCT2071200056已完成不适用
Safety, tolerability and pharmacokinetics of single rising oral doses and multiple oral doses of BI 1323495 versus placebo in healthy male Japanese subjects genotyped as poor and extensive metabolizers of UGT2B17 (single-blind, randomised, placebo-controlled [within dose groups] trial), including an investigation of drug-drug interaction with itraconazole in healthy male subjects genotyped as poor metabolizers of UGT2B17 (an open-label, two-period, fixed sequence trial)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 74
- 主要终点
- percentage (%) of subjects with drug-related adverse events
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Other
- 盲法
- Single Blind
入排标准
- 年龄范围
- 20age old over 至 45age old under（—）
- 性别
- Male
入选标准
- •Healthy male subjects according to the assessment of the investigator, as based on a complete medical history, including a medical examination, vital signs (BP, PR), 12-lead ECG, and clinical laboratory tests
- •Japanese ethnicity, according to the following criteria:
- •born in Japan, have lived outside of Japan <10 years, and have parents and grandparents who are Japanese
- •Age of 20 to 45 years (inclusive) at screening
- •BMI of 18.5 to 25.0 kg/m2 (inclusive) at screening
- •Signed and dated written informed consent prior to admission to the trial, in accordance with Good Clinical Practice (GCP) and local legislation
- •Subjects who agree to minimize the risk of making their partner pregnant by fulfilling any of the following criteria starting from the first administration of trial medication until 90 days after last administration of trial medication
- •Use of adequate contraception, any of the following methods plus condom: intrauterine device, combined oral contraceptives that started at least 2 months prior to the first drug administration.
- •Vasectomized (vasectomy at least 1 year prior to enrolment)
- •Surgical sterilization (including bilateral tubal occlusion, hysterectomy or bilateral oophorectomy) of the subject's female partner
- •Subjects genotyped as UGT2B17 poor metabolizers, i.e. carrying allele of UGT2B17 gene (2/2) (DDI and MD part only)
排除标准
- •Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator
- •Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 40 to 90 mmHg, or pulse rate outside the range of 40 to 99 bpm
- •Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
- •Any evidence of a concomitant disease assessed as clinically relevant by the investigator
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
- •Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
- •History of relevant orthostatic hypotension, fainting spells, or blackouts
- •Chronic or relevant acute infections (Subjects who were positives to Hepatitis B surface antigen, Hepatitis B surface antibody, Hepatitis B core antibody, Hepatitis C antibodies, HIV-1 and HIV-2 antigen and/or antibody, T-SPOT and Syphilis test)
- •History of relevant allergy or hypersensitivity (including allergy to the trial medication or its excipients)
- •Use of drugs within 30 days of planned administration of trial medication that might reasonably influence the results of the trial (including drugs that cause QT/QTc interval prolongation)
- •Intake of an investigational drug in another clinical trial within 3 months (4 months for new active ingredients) of planned administration of investigational drug in the current trial, or concurrent participation in another clinical trial in which investigational drug is administered
- •Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
- •Inability to refrain from smoking on specified trial days
- •Alcohol abuse (consumption of more than 30 g per day for males)
- •Drug abuse or positive drug screening
- •Blood donation of more than 400 mL within 12 weeks or 200 mL within 30 days or plasma donation within 2 weeks prior to administration or intended blood donation during the trial
- •Intention to perform excessive physical activities within one week prior to the administration of trial medication or during the trial
- •Inability to comply with the dietary regimen of the trial site
- •A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are repeatedly greater than 450 ms in males) or any other relevant ECG finding at screening
- •A history of additional risk factors for Torsade de Pointes (such as heart failure, hypokalaemia, or family history of Long QT Syndrome)
- •Subject is assessed as unsuitable for inclusion by the investigator, for instance, because the subject is not considered able to understand and comply with trial requirements, or has a condition that would not allow safe participation in the trial
- •History of disease that affects the present situation
- •Current or history of relevant kidney, urinary tract diseases or abnormalities (e.g. nephrolithiasis, hydronephrosis, acute or chronic nephritis, renal injury, renal failure)
- •Estimated glomerular filtration rate according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula < 80 mL/min at screening
- •Within 10 days prior to administration of trial medication, use of any drug that could reasonably inhibit platelet aggregation or coagulation (e.g. acetylsalicylic acid)
- •History of drug induced liver injury
- •Liver enzymes (ALT, AST, Gamma-Glutamyl Transferase [GGT]) above upper limit of normal at the screening examination
- •Known relevant immunodeficiency, as judged by the investigator
- •History and/or presence of tuberculosis; positive result for interferon gamma release assay (IGRA) (i.e. T-SPOT), or history of pneumococcal infection
- •Axillary temperature of more than 37.7oC on Day -1
- •Subjects who have received live or live-attenuated vaccine in the 4 weeks prior to dosing
- •C-reactive protein above upper limit of laboratory reference range at screening
结局指标
主要结局
percentage (%) of subjects with drug-related adverse events
to assess safety and tolerability of BI 1323495
次要结局
- Cmax
- AUC0-
- AUC0-tz
- AUC0-12(After the first dose)
- AUCT,ss(After the last dose)
- Cmax,ss(After the last dose)
研究者
相似试验
已完成
不适用
A study in healthy Japanese men to test how well different doses of BI 1291583 are toleratedjRCT2071210111Nippon Boehringer Ingelheim Co., Ltd.36
进行中（未招募）
不适用
A study in healthy Japanese men to test how well different doses of BI 3006337 are toleratedNon-alcoholic SteatohepatitisjRCT2031230638Boehringer Ingelheim36
已完成
不适用
A study in healthy Japanese men to test how well different doses
of BI 1569912 are toleratedjRCT2071210037Nippon Boehringer Ingelheim Co., Ltd.44
已完成
不适用
A study in healthy Japanese men to test how well different doses of BI 765845 are toleratedjRCT2031230092Boehringer Ingelheim32
暂停
不适用
A study in healthy Japanese and Chinese men to test how well different doses of BI 706321 are toleratedjRCT2071210105Nippon Boehringer Ingelheim Co., Ltd.60